Ashland Announces Klucel xtend HPC Matrix Former
Klucel xtend HPC is the latest addition to the company’s Klucel product line and further expands their controlled-release portfolio.
Ashland announced the introduction of Klucel xtend hydroxypropyl cellulose (HPC) controlled release matrix former on Oct. 3, 2022. It is designed to deliver process versatility and release profile efficiency.
According to a company press release, Klucel xtend HPC has been shown to match the release profile of widely used Hypromellose controlled-release formulations at half the polymer concentration. Prior to this product launch, Ashland claims that there were limited options for managing the release profile of controlled release formulations, especially high dose.
The reduced polymer concentration offers the possibility of smaller pills or higher dosage, presenting an option for easier tablet swallowability or a reduction in the number of tablets required for frequent medication. According to the release, this feature is intended to improve patient compliance with drug regimens.
Source: Ashland
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
